Biopharma | November 28, 2025
Exyte completes Pharmaplan integration
Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division
Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division
Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway
Renalyx will continue operating as an independent unit within the group
The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA submission and commercialization of the product in the US
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
CD388 is administered as a single 450-milligram subcutaneous dose in adults and adolescents
The viewer aims to help radiologists work smarter, faster, and more collaboratively, while reducing IT complexity and freeing up valuable clinical time
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Subscribe To Our Newsletter & Stay Updated
